Traditional methods for identifying high-affinity, antigen-specific antibodies, such as ELISA and flow cytometry, have long been essential tools in therapeutic development. But they’re not without their limitations: laborious wash steps, potential antigen denaturation, and complex data analysis can slow progress.

SYNENTEC’s Antibody-Binding application note introduces a game-changing alternative. By leveraging high-throughput microscopy with the NYONE Scientific imaging system, this method eliminates the need for washing steps, utilises minimal sample volumes, and delivers high sensitivity-detecting primary antibodies as low as 1 ng/mL.

This innovation simplifies the screening process while improving both reproducibility and accuracy, making it an invaluable asset for verifying monoclonality and screening hybridoma supernatants.

Incorporating such innovative technologies can significantly accelerate the development of therapeutic antibodies, paving the way for more efficient and effective treatments. Read the application note below.